{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125455","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.128088+00:00","generated_at":"2026-05-30T01:38:21.054080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyra Therapeutics Q3 net loss $11.9M; ENLIGHTEN 2 topline due Q2 2025","bullets":["Cash & equivalents $51.6M as of Sep 30, 2024; runway into Q1 2026.","R&D expenses fell to $5.9M from $12.4M YoY; G&A down to $3.9M from $5.0M.","ENLIGHTEN 2 pivotal trial fully enrolled Oct 2024; topline results expected Q2 2025.","ENLIGHTEN 1 extension study showed no product-related serious adverse events.","Net loss improved to $11.9M vs $15.7M in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125455","json":"https://secwatch.observer/filing/0000950170-24-125455.json","markdown":"https://secwatch.observer/filing/0000950170-24-125455.md","text":"https://secwatch.observer/filing/0000950170-24-125455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/0000950170-24-125455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/lyra-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:38:21.054080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}